Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52‐week, randomized, double‐blind, active‐controlled, parallel‐group study

@article{Bosi2011AlogliptinAA,
  title={Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52‐week, randomized, double‐blind, active‐controlled, parallel‐group study},
  author={Emanuele Bosi and Graham Ellis and C. Wilson and Penny Fleck},
  journal={Diabetes},
  year={2011},
  volume={13}
}
Aim: To assess the efficacy and safety of adding alogliptin versus uptitrating pioglitazone in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone. 
Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with Type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study
To investigate the efficacy and safety of the dipeptidyl peptidase‐4 inhibitor linagliptin in patients with Type 2 diabetes mellitus inadequately controlled by a combination of metformin and
Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study
To evaluate the long‐term durability of the efficacy of alogliptin compared with glipizide in combination with metformin in people with type 2 diabetes inadequately controlled on stable‐dose
Alogliptin – the new member of DPP-4 inhibitors class
TLDR
Alogliptin, a new representative of the DPP-4 inhibitors, in adult patients with type 2 diabetes mellitus (DM type 2) as monotherapy or in combination with metformin, pioglitazone, glibenclamide and insulin is presented.
Safe prescribing of metformin in diabetes
Metformin is the first-line pharmacological therapy for type 2 diabetes. It is the only glucose-lowering oral drug that has been shown to reduce mortality in patients with diabetes. The most common
Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus
TLDR
The cardiovascular profile of the dipeptidyl peptidase‐4 inhibitor alogliptin is evaluated and concerns that some classes or agents for the treatment of type 2 diabetes may increase CV risk are investigated.
Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
TLDR
Clinical trial data with alogliptin demonstrate clinical efficacy in terms of glycosylated hemoglobin A1c and fasting plasma glucose reductions when used both as monotherapy and as a component of two- or three-drug combination regimens for the treatment of T2DM.
Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
TLDR
This resolution provides an expert council opinion on the feasibility of using a combination of alogliptin and pioglitazone in patients with type 2 diabetes.
Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin
 This paper discusses the possibilities and benefits of early combination therapy and the application features of a fixed-dose combination of metformin and alogliptin (Vipdomet®) in the treatment of
The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
TLDR
The ENDURE trial and the present cost-effectiveness analysis found that the glycemic durability of alogliptin therapy was associated with improved long-term patient outcomes, QALY gains, and ICERs that were cost-effective when evaluated against standard threshold values.
Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
TLDR
Benefit-risk assessment indicates that DPP-4is, including alogliptin, are important treatment options, especially for Asian patients with T2DM, for whom they have potential as a first-line therapy.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
Efficacy and safety of adding the dipeptidyl peptidase‐4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double‐blind, placebo‐controlled study
Aims:  To evaluate the efficacy and safety of alogliptin, a new dipeptidyl peptidase‐4 inhibitor, for 26 weeks at once‐daily doses of 12.5 and 25 mg in combination with metformin in patients whose
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia
Aims: To assess the efficacy and safety of alogliptin added to insulin in patients with type 2 diabetes inadequately controlled with insulin alone or combined with metformin.
Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
Aim:  To evaluate the efficacy and safety of alogliptin, a potent and highly selective dipeptidyl peptidase‐4 (DPP‐4) inhibitor, in combination with glyburide in patients with type 2 diabetes
Metformin revisited: re‐evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents
TLDR
The role of metformin as initial therapy and in combination with these newer drugs for treatment of type 2 diabetes mellitus (DM) is evaluated.
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
TLDR
Saxagliptin once daily added to meetformin therapy was generally well tolerated and led to statistically significant improvements in glycemic indexes versus placebo added to metformin in patients with type 2 diabetes inadequately controlled with met formin alone.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study*
TLDR
Addition of alogliptin to pioglitazone therapy significantly improved glycemic control in patients with type 2 diabetes and was generally well tolerated.
Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.
TLDR
Saxagliptin added to TzD provided statistically significant improvements in key parameters of glycemic control vs. TZD monotherapy and was generally well tolerated.
Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes
TLDR
Alogliptin plus pioglitazone combination treatment appears to be an efficacious initial therapeutic option for type 2 diabetes.
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
  • N. Mikhail
  • Medicine
    Vascular health and risk management
  • 2008
TLDR
The combination of sitagliptpin or vildagliptin with pioglitazone can be a useful therapeutic approach in patients with type 2 diabetes who cannot tolerate metformin or a sulfonylurea.
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control
TLDR
Alogliptin monotherapy was well tolerated and significantly improved glycemic control in patients with type 2 diabetes, without raising the incidence of hypoglycemia.
...
1
2
3
4
...